WORK VISIT AND STRATEGIC MEETING OF THE BOARD OF COMMISSIONERS OF BIOFARMA GROUP

Thursday, May 8, 2025, The Board of Commissioners of PT Biofarma (Persero) Tugas Ratmono, along with the members of the Integrated Governance Committee (KTKT) and the Board of Commissioners of PT Kimia Farma Tbk, Suprianto, conducted a work visit on Thursday, May 8, 2025, to PT Phapros Tbk. The visit was warmly welcomed by the President Commissioner of Phapros, Maxi Rein Rondonuwu, along with the Board of Directors of Phapros, including the Acting President Director of Phapros, Ida Rahmi Kurniasih, Marketing Director Maraja Jeson Siregar, and Director of Finance, Risk Management, and Human Resources Yudhi Rangkuti.

This work visit is part of the supervisory duties of the Biofarma Group's Board of Commissioners to ensure the effectiveness of the Integrated Corporate Governance Process across all subsidiaries and affiliates. The event also serves as part of the Integrated Governance Committee's role in enhancing coordination, transparency, and driving the performance and sustainability of the subsidiaries.

The event began with introductions and an opening of the meeting, followed by presentations on Phapros' profile and performance, risk profile, and PEHA recovery strategy. In his remarks, the President Commissioner and Independent Commissioner of PT Bio Farma (Persero), Tugas Ratmono, shared his directions and expectations for PT Phapros Tbk.

"In the next 5 years, we must truly lay a stronger foundation to achieve Indonesia Gold 2045. Phapros must grow and be well-managed for the sake of our future generations and to provide added value, both economically and for national health strength," said Tugas.

In her presentation, Acting President Director Ida Rahmi Kurniasih outlined 5 main grand strategies in business and financial transformation efforts to restore Phapros, which are:

1. Product Innovation and Portfolio Diversification

2. Market Expansion and Strategic Partnerships

3. Strengthening Financial Performance

4. Strengthening Human Resources (HR)

5. Optimizing Subsidiary Performance

Later in the afternoon, a factory visit to Phapros' production facility and laboratory was conducted. This field visit was part of the Board of Commissioners and Integrated Governance Committee’s efforts to directly supervise, collaborate, and unite forces. It ensured that the direction of transformation remains on track for execution.

At the end of the event, Tugas Ratmono conveyed that we must all build a culture of hard work, speed, and how to manage the company efficiently. We must grow and stay alert, not be complacent, so that we can achieve our goals, the company's goals, and the country's goals successfully.

"Let us rise together with good intentions. We must work hard, work smart, and work fast to win the market. Let’s be leaders with character, competence, and commitment," said Tugas, closing the Biofarma Group Board of Commissioners Work Visit and Strategic Meeting.

Corporate governance is not just a procedure but a commitment reflected in every operational detail. Hopefully, with collaboration from the holding company to the subsidiaries, we can continue to strengthen integrated governance. Maintaining Phapros' sustainability means ensuring public access to trusted medicines and supporting national pharmaceutical resilience, today, tomorrow, and beyond.